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resumo 
 
 
Este relatório pretende relatar as actividades por mim 
desenvolvidas durante o meu estágio no INFARMED, I.P., mais 
concretamente na Direção de Produtos de Saúde. 
Estando os dispositivos médicos dentro de um complexo sistema 
de regulamentação, este relatório começa por uma introdução 
aos assuntos regulamentares associados aos dispositivos 
médicos, e posteriormente a um relato das actividades 
desenvolvidas, principalmente ao nível da validação de registos 
de Distribuidores. 
Tratando-se de produtos com finalidade médica e portanto 
usados no contexto da saúde, a sua segurança e o desempenho 
dos dispositivos são conceitos fundamentais aquando da 
avaliação destas tecnologias. O surgimento de novas tecnologias 
a um ritmo exponencial faz deste sector uma área em constante 
expansão e dinamismo. Assim sendo este é um sector com 
bastantes desafios para o próprio profissional, mas que também 
acompanha o bem-estar dos utilizadores durante toda a sua vida. 
 
 
  
 
   
  
keywords 
 
Medical device, conformity, CE mark, safety, performance, registries, 
distributor, manufacturer, authorised representative. 
 
summary 
 
The present report is intended to describe the activities done 
during my internship in INFARMED, I.P., more specific in the 
Health Products Directorate.  
Since the medical devices are part of a complex regulatory 
system, this report starts by a brief introduction to medical 
devices’ regulatory affairs, and then a description of the activities 
done, mainly in the validation of the Distributors’ registries. 
Being these products with a medical intended, and thus used in 
the health sector, the safety and performance of the products are 
the main concepts in the evaluation of these technologies. The 
accelerated time until the raise of new technologies makes this 
sector an area in constant expansion and dynamism.  
Therefore this sector present many challenges for the 
professional, but at the same time goes along with the well-being 
of the users during all theirs life’s. 
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1 Introduction 
This report is intended to report the work done at INFARMED during my 9 months 
internship. However more than a work experience, this internship represents a unique 
opportunity to understand the medical device (MD) universe, from the side of the national 
authorities, which in medical device has a different role when compared to the drugs 
market. This training will complement the issues addressed during the university course, 
allowing me to obtain the final grade necessary for the conclusion of the master degree on 
Pharmaceutical Medicine.  
During my course, the regulatory issues related to MD weren’t one of the topics over 
explored, so my initial knowledge about it is a little limited. The main objective for this 
internship is to understand the complexity of place MD on the market, which are in 
compliance with the national and European rules. Since it is a huge goal, the better way to 
accomplish it is by settle more specific goals, like: 
 Know the applicable European legislation to the MD sector, and the particularities 
of the national law; 
 Understand the role of the national authorities on the MD market; 
 Understand the meaning of market conformity and the CE mark; 
 Identify the different steps for market conformity; 
 Understand the MD’s classification and how it affects the conformity evaluation. 
Nevertheless there are as well other outcomes, more related to soft skills that can be only 
acquired with work experience, and are dependable of the type of work I’m going to do.  
As so, my internship will consist mainly at the use of different functionalities of the 
database SDIV. This will include the validation and verification of the information 
available in the MD registries made by the distributors. Additionally it will comprise the 
verification of the documentations which demonstrate the conformity of the MD with the 
applicable legislation. These activities will be performed in order to accomplish the 
objectives stated above, and also to develop the necessary knowledge related to MD’s 
regulatory affairs. 
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1.1 INFARMED, I.P. 
INFARMED, I.P. – National Authority of Medicines and Health Products, I.P., is the 
Portuguese’s national authority responsible for regulate and supervise medicinal products, 
medical device, cosmetic and products for body care, according to the applicable national 
and international laws. 
(4)
 
During 1993, the European Commission (EC) had elaborated a proposal to create a 
European Agency of Medicines. This proposal had foreseen an active role from the 
different national authorities and the experts of the European Community on medicine 
related issues. Consequently it was seen as necessary to have a national institute with the 
technical capabilities on the field, been at the same time strong and independent. In this 
way, by the application of the Decree-law nº 353/93, INFARMED, I.P. was created, with 
the necessary administrative and economic autonomy. 
(5)
 
Nowadays INFARMED, I.P structure can be decomposed on three, the management 
bodies, business functions and the supporting functions, each one contributing to the global 
mission of the institute. In total there are five management bodies, three units of supporting 
functions and seven units with business function (see Figure 1). 
(6)
 
1.1.1 Health Products Directorate 
It was on the Health Products Directorate – Direção de Produtos de Saúde (DPS), business 
unit, that my internship had occurred. This Department is responsible for regulate, 
monitoring and by the surveillance of the conformity of the health products’ market. 
Additionally it also plays a role in the establishment of the requirements for the clinical 
investigation with Health Products and evaluates the applications for clinical investigation. 
Another activity is related to the designation of new Notified Body (NB), and on 
monitoring the national ones, considering its role on market conformity. By doing this DPS 
is ensuring that the health products, which circulate on the national market, are in 
conformity with the requirements of the applicable legislation, and are safe for human use 
and in accordance to the performance stated by the manufacturer. 
(7, 8)
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Although formally there is only one subunit at DPS, the reality is that DPS is subdivided in 
three functional areas. Being Health Products Vigilance Unit (UVPS) the official subunit 
of DPS, it is responsible for ensure the activities related to manufacturer’s incidents 
reports, from the mechanism of collection of the information to the risk-benefit analysis 
and implementation of the safety measures related to the normal use of MD. It’s also 
UVPS that coordinates the activities of the maintenance and disclosure of the national 
vigilance system on MD, and manage the information created by the European Union on 
the MD vigilance. The two unofficial subdivisions are for the issues related to the market 
surveillance, one for the MD and the other for cosmetics. 
(9, 10)
 
The DPS duties allow this unit to be an active participant in the public health protection. 
Figure 1 – INFARMED, I.P. organizational chart (1); orange represent the business 
units, and white blue represent the support units 
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1.1.2 Quality Management System of INFARMED, I.P. – ISO 9001 
During my internship my colleagues clearly stated the importance of having an 
implemented Quality Management System (QMS). Their importance can be seen in an 
equal service for all the clients, but it also works as a safeguard for the institution. The 
QMS guarantee to the institution that it provides a quality service to clients, at the same 
time that it allows the identification of issues/problems, or potential improvements, and the 
consequent upgrade of the system. This is a reality in INFARMED, I.P. since they had 
implemented the ISO 9001. In my opinion the QMS just work as well as I had seen, due to 
the commitment of all the employees to make it work, as a plus they also transmit this 
feeling to the recently arrived workers. 
1.1.2.1 Quality Manual 
The quality manual of INFARMED, I.P. is available for all partner and clients at the 
institution website. Contrary to other companies, and as foreseen in the QMS, there are no 
controlled copies of the manual. It is available for all the collaborators in an informatics 
platform, as also all the procedures and other quality’s documents. (11) 
There we can have an overview of the QMS of INFARMED, I.P. regarding the application 
of ISO 9001, its documental structure and the informatics control of data. We are also 
introduced to the available processes which are covered by the QMS. 
(11)
  
1.1.2.2 Quality Policy 
INFARMED, I.P.’s quality policy is based in four essentials supports that together allow 
the accomplishment of their mission. (see Figure 2). This supports include: 
(12)
 
 Guarantee the accomplishment of the applicable legal requirements: 
o An INFARMED, I.P. duty: regulate and supervise it, both for economic 
entities, products and health’s professionals; 
o Qualified employees to play their roles according to the laws. 
 Fulfil clients and partners expectations and needs: 
o Identification of clients and partners requirements; 
o Evaluate quality of services, including timings and avoiding conflict of 
interests. 
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 Workers' training/qualifications: higher importance taking in account the 
INFARMED, I.P.’s mission; 
 Upgrade the process and efficacy of the QMS. 
Figure 2 – Quality policy of INFARMED,I.P. (12) 
1.2 State-of-the art 
Although the concepts are similar, both here and in the United States of America, the 
process itself to been able to put on the market a MD is quite different. There is some 
arguing around whose system is the better one, however in my own opinion they are just 
different. One is not better than the other. This section will be dedicated to explain the 
European system, since it was the background for my internship. 
1.2.1 European System 
The European framework for MD evaluation is actually based in the so called “New 
Approach”. This is based on the application of essential requirements, settled in the 
applicable legislation. The intended is to harmonise the requirements across Europe, 
allowing the free movement of goods. In order to achieve the harmonisation the following 
principles were established: 
(13)
 
 Legislative harmonisation applies to essential requirements (mainly performance 
and functional requirements) of products place on the EU market; 
 The technical specification, which meets the essential requirements, should be laid 
down in harmonised standards; 
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 Compliance with the harmonised standards may represent the conformity with the 
essential requirements of the applicable legislation; 
 Application of harmonised standards or others stills voluntary. 
With the “New Approach” Member states should not limit the free movement of goods in 
their market of the products which was been correctly evaluated, which means it must be 
bearing a CE mark and be in conformity with the applicable legislation. This is valid for a 
huge variety of products such as elevators, mobile phones, medical devices, software, or 
even toys. 
(13)
 
The “New Approach” also relies on the principle of the responsibility and credibility of the 
participation of all the involved parties (manufacturers, NB, standardization bodies, 
Competent Authority (CA) and the users) in order to allow the system to properly work. 
Nevertheless the responsibility for the MD conformity belongs to its manufacturer. 
(14)
 
As my internship was related to MD only this kind of products will be address in this state-
of-art, although the main principles are similar to other product types under the “New 
Approach”, with the appropriate specifications for each product, such as the vigilance for 
MD. 
 
Figure 3 – Overview of the “New Approach” applied to Medical Devices; adapted from 
Neves J 
(14, 15)
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According to the Council Directive 93/42/EEC, a MD is defined as: 
(2)
 
“any instrument, apparatus, appliance, software, material or other article, whether used 
alone or in combination, including the software intended by its manufacturer to be used 
specifically for diagnostic and/or therapeutic purposes and necessary for its proper 
application, intended by the manufacturer to be used for human beings for the purpose of: 
- diagnosis, prevention, monitoring, treatment or alleviation of disease, 
-  diagnosis, monitoring, treatment, alleviation of or compensation for an injury or 
handicap, 
-  investigation, replacement or modification of the anatomy or of a physiological 
process, 
-  control of conception, 
and which does not achieve its principal intended action in or on the human body by 
pharmacological, immunological or metabolic means, but which may be assisted in its 
function by such means;” 
In this definition a large number of products may be included, from a simple dressing to a 
complex pacemaker. The main criteria is that the product present, as foreseen by the 
manufacturer, a medical intended, not achieved by pharmacological, immunological or 
metabolic means. It is considered three main classes of MD, the Active Implantable 
Medical Devices (AIMD), the In Vitro Diagnostic Medical Devices (IVD) and the Medical 
Devices (class I to III). These different classifications reflect the different risk posed by the 
different devices, which allows to adequate the necessary legal requirements. 
(2, 3, 16-20)
  
Actually in the European framework there is a different Directive for each of the above 
indicated MD. The Directive 93/42/EEC, as its amended, is related to Medical Devices.  
For AIMD, the Directive 90/385/EEC settles the appropriate requirements for place into 
the market, and defines AIMD as “any active medical device which is intended to be totally 
or partially introduced, surgically or medically, into the human body or by medical 
intervention into a natural orifice, and which is intended to remain after the procedure”. 
These directives were transposed to the Portuguese national’s law at the Decree-law no 
145/2009 (See Table 1). 
(2, 16, 18)
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Regarding the IVD, and according to the Directive 98/79/EC, as transposed at national’s 
law at Decree-law no189/2000 (See Table 1), IVDs are defined as: 
(19, 20)
 
“any medical device which is a reagent, reagent product, calibrator, control material, kit, 
instrument, apparatus, equipment, or system, whether used alone or in combination, 
intended by the manufacturer to be used in vitro  for the examination of specimens, 
including blood and tissue donations, derived from the human body, solely or principally 
for the purpose of providing information: 
- concerning a physiological or pathological state, or 
-  concerning a congenital abnormality, or 
- to determine the safety and compatibility with potential recipients, or  
- to monitor therapeutic measures.” 
Table 1 – Listing of the main European Directives and the corresponding transposal 
for Portuguese’s national law (21) 
Although different classification for MD may exist, the principles are the same. There is a 
manufacturer who wants to market a product. The manufacturer will be the one responsible 
for the MD compliance, and to prove its conformity with the applicable legislation. If 
needed the MD will be evaluated by a NB, or only by the manufacturer before affix the CE 
mark. Then the manufacturer should register its product in the appropriate CA. 
European Directive National transposition 
Directive 90/385/EEC – AIMD 
Decree-law no 145/2009 Directive 93/42/EEC – MD 
Directive 2007/47/EC – Revision to AIMDD and MDD 
Directive 98/79/EC - IVD Decree-law no 189/2000 
Directive 2000/70/EC – MD with Human Blood Derivatives 
Decree-law no 145/2009 
Directive 2003/32/EC – MD with Animal Origin Derivatives 
Directive 2003/12/EC – reclassification of Breast Implants Decree-law no 259/2003 
Directive 2005/50/EC – reclassification of Implantable 
Prosthesis 
Decree-law no 258/2007 
Note: Regulations are not stated here since they are not transposed to national law. 
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Additionally the manufacturer needs to continuously verifying the MD’s conformity 
regarding all the data collected on the use of the device. This was a brief overview of the 
life cycle (see Figure 4) of a MD, since it will be detailed in the following sections. 
(2, 16, 18-
20, 22)
 
 
Figure 4 – Medical Device’ life cycle, adapted (22) 
From this overview we are able to state that the main responsibility will be attributed to the 
manufacturer. As so the manufacturer is the person or entity responsible for one or more of 
the following activities: design, manufacture, packaging and labelling. However if the 
manufacturer does not have a registered place of business in the Community, he shall 
designate an Authorised representative, who will assume some of the manufacturer’s 
responsibilities, including being an interlocutor between the involved entities 
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(manufacturer and CAs). From now on when referring to manufacturer, I’m also referring 
to its Authorised Representative, if applicable. 
1.2.1.1 Classification and Borderline 
The first step to be able to market a device is to be sure about its true qualification. As so 
the manufacturer needs to evaluate if its product fulfil the MD’s definition (stated above in 
section 1.2.1), or in other hand if its products is not a MD. When it’s not clear if the 
product falls under the MD legislation, then the manufacturer may ask its national CA for 
advice. It is important that first the manufacturer consult the guidance on classification and 
qualification of MD available at the Commission’s website.  There the different 
stakeholder may consult numerous guidances on different subjects.   These draft 
documents works as guidelines which can be used by stakeholders, however they are not 
legally binding. These documents are generally called MEDDEVs and offers guidance for 
the correct application of the rules and regulatory requirements applicable to the European 
System. The MEDDEV 2.4 present the applicable rules for MD classification as also give 
some examples of MD for each rule. 
(23)
 
Additionally there is available a Borderline Manual, which also resulted from the 
discussion of the Medical Devices Expert Group on Borderline. During the discussion on 
the Medical Devices Expert Group on Borderline and Classification are represent the CA, 
the Industry, the NBs, the Standardisation Bodies and COM services. 
(24)
 The manual on 
Borderline has already some entries of borderline issues (when it’s not clear if the product 
fall under a MD legislation or not) which help to clarify and ensure the uniformity of the 
approaches in all the member states. There are essentially specific entries related to 
products from which had arisen doubt’s regarding its qualification and classification. (25, 26)  
When determining the qualification of the product, the manufacturer should look to the 
main purpose of the products and to the available scientific data. If the product has a 
medical purpose, it could be a MD or a medicinal product. Otherwise it will fall under 
other legislation, such related to biocides, software and cosmetics (see Figure 5 for 
frequent borderlines). The second part is to verify the main mode of action, also relying on 
scientific/clinical data. If is pharmacological, immunological or metabolic, then the 
product will be a medicinal product. If not the product is a MD. When doubt still exist 
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them by application of the article 2 of the Directive 2001/83/EC, it should be applied the 
Directive 2001/83/EC (legislation for medicinal products) to the product. 
(26-28)
 
 
Figure 5 – Borderline with Medical Devices, common qualification (28); PPE – Personal 
protection equipment 
As far as the qualification is settled, the manufacturer may think about its classification. 
The MD legislation based its medical device classification according to the risk present by 
the device.  
1.2.1.1.1 Medical Device 
Relating to MD in general their classification is settled according to three major criteria: 
the intended use, the invasiveness and the duration of use. 
(2, 3, 18)
 
 Intended use: the one claimed by the manufacturer and stated at the technical 
documentation, including, but not limited to Instructions of Use, Labels and 
promotional materials; 
 Invasiveness of the device; 
o Non-invasive devices; 
o Invasive devices: 
 Body orifice invasiveness – penetrates through natural openings of the 
body or a permanent artificial opening; 
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 Surgically invasive – penetrates through the body surface in the context 
of a surgical operation: 
- Reusable surgical instruments – instruments for surgical use that can 
be reused; 
- Implantable devices – intended to be introduced in the body in a 
surgical context and to remain there after the procedure ends; 
 Duration of the contact with the patients: 
o Transient use – for less than 60 minutes; 
o Short term use – use between 60 minutes and 30 days; 
o Long term use – use in more than 30 days. 
These criteria allow the manufacturer to determine the device classification. As said before 
the classification of the MD represents its associated risk. So as higher the classification of 
the device, the higher will be the risk associated to the device. This will also represent 
different approaches of conformity evaluation for each MD class. These MD are classified 
in: 
(2, 3, 18)
 
 Class I – considered to have low risk, some initial issues should be considered in 
assess the associated risk, such as sterility and measuring function; 
 Class II – medium risk associate: 
o IIa; 
o IIb; 
 Class III – high risk medical device. 
In order to attribute the correct classification the manufacturer must follow the rules 
present at the annex IX of Directive 93/42/CEE. Using the rule that most fits the medical 
device and its intended use. In those cases where more than one rule can be applied, the 
manufacturer should follow the one that attribute the higher class to the medical device. 
The mentioned rules can be divided in four sets of rules: (see Figure 6) 
(2, 3, 18)
 
 Non-invasive medical devices: from rule 1 to 4; 
 Invasive medical devices: from rule 5 to 8; 
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 Active medical device: from rule 9 to 12; 
 Special rules: from rule 13 to 18. 
1.2.1.1.2 Active Implantable Medical Device 
Devices classified as AIMD are implantable devices with a source of energy that convert 
the energy from the source into another type of energy. Taking in account the nature of the 
devices they are associated to a high risk, as so they are classified as itself, as AIMD, 
according to their own Directive (90/385/EEC). 
(16, 18)
 However the available draft 
regarding the new regulation for MD, others than IVD, foresees that AIMD will be 
classified as class III. 
(4)
 
1.2.1.1.3 In vitro Diagnostic Medical Device 
In this case the risk is associated with the consequences of failure of the test (false 
positives and false negatives), and not with the direct risk for the user, as so their 
classification principles are different from the others medical devices.  According to 
Directive 98/79/EC, IVD’s are classified in: (17, 20) 
 Self-testing IVD – devices to be used by lay persons; 
 General IVD – intended to be used by trained professionals. The IVD’s that are 
essential to medical performance and whose failure represent a serious risk for 
patients or public health are listed, and classified as: 
o List A; (see Annex A) 
o List B; (see Annex A) 
o Other – general IVD that do not fall under the list A or B. 
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Figure 6 - Rules according to Directive 93/42/EEC 
(2, 3)
 
 CNS – Central Nervous System; CCS – Central Circulatory System 
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1.2.1.2 Clinical Evaluation 
One of the information that must be contained in the technical file is related with the 
clinical information regarding the MD, this information will and should support the safety 
and performance of the device. Although this information should be available before affix 
the CE mark, this is a continuous process during all the life cycle of a MD. This 
information may be collected by means of: 
(29, 30)
 
 Clinical investigation 
 Literature search of a similar device, for which manufacturer had demonstrate the  
equivalence of the MD; 
 Clinical experience: comprise the clinical use of the device and the post-market 
activities. 
The comprehensive analysis of the available pre- and post-market clinical data is seen as 
the clinical evaluation, which may arise from the above mentioned sources. Figure 7 
illustrate the necessary steps to perform a clinical evaluation. An additional step, which is 
not indicated in Figure 7, comprises the identification of the relevant essential requirement 
which need to be supported from clinical data. This identification helps in defining the 
clinical evaluation scope. 
(29)
 
The scope of the clinical evaluation may be defined only after identifying the essential 
requirements to be addressed on the clinical evaluation, and taking into account: 
(29)
 
 Any design features, from which may arise safety and performance concerns; 
 The intended purpose and site of application; 
 Any other specific claim made by the manufacturer; 
 The presence or not in the market of a similar device; 
 The types and sources of data that can be used. 
Since the scope is defined then the manufacturer should identify the available clinical data, 
appraise it, and evaluate if he had collect the necessary information, or in the other hand if 
he needs to generate it. 
(29)
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Figure 7 - Steps for a clinical evaluation 
(29)
 
When evaluating the collected information the manufacturers should have in account if the 
data they are using are from the same device or in other hand from similar devices. If it 
comes from similar devices, it’s necessary to prove that the devices are equivalents (the 
comparative device should already be placed on the market). In order to prove equivalency 
the manufacturer should demonstrate the similarities between clinical, technical and 
biological characteristics of the devices (more information on Table 2). 
(2, 18, 31, 32)
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Table 2 – MD’s characteristic to take in account on equivalency (31, 32) 
If from the evaluation of the collected data, there still need more information to fulfil the 
essential requirements, then the manufacturer should generate clinical evidence. In order to 
generate it, manufacturer should promote clinical investigations (note that clinical 
evaluation is different from clinical investigation). 
(29)
 
To start any clinical investigation, according to ISO 14155 and the applicable directives, 
for AIMD, class III and implantable and long-term invasive devices, the ones that are 
classified as IIb and IIa, the manufacturers should notify within a maximum of 60 days the 
CA where the study will be conducted. This should be the full application for notification. 
However manufacturer should ensure that the process had already been approved by the 
local Ethic Committee, as well by the National Data Protection Authority (National 
Commission on Data Protection (CNPD) in Portugal). At the end the manufacturer should 
also send the report on clinical evaluation to the CA. 
(2, 16)
 
Since clinical evaluation should be conducted as well on post-market, some clinical 
investigations should as well be made. For those devices with a valid CE mark (except 
AIMD) that are under clinical investigation, it’s not necessary to notify it, unless the device 
is not used for the same purpose as stated on the conformity process. 
(2, 16, 18)
  
Recently in Portugal a new law is applied to MD, the intended of law number 21/20014 is 
to uniform, as far as possible, the criteria for medicines, MD and cosmetics. This law had 
modified the way of notification of Clinical investigations in Portugal. Now the 
manufacturer must submit to INFARMED, I.P. and to the Ethic Comission on Clinical 
Investigation (CEIC) simultaneously, by way of an informatic platform (foresseen in the 
law, but not already working). CEIC will be the ethic committee responsible for the ethical 
evaluation, however he can delegate this activity to local ethic committees where the 
clinical investigation will be conducted. 
(33)
 
Clinical Technical Biological 
- Intended use; 
- Severity and stage of disease; 
- Site of application; 
- Patient population; 
- Clinical performance. 
- Specifications and physiochemical properties; 
- Critical performances requirements; 
- Principles of operations and use’s conditions; 
- Related to the device design. 
- Biocompatibility of 
the materials on same 
bodies’ tissues/fluids. 
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This new laws also modified the way INFARMED, I.P. should react in relation to a clinical 
investigation notification. Until the application of Law no 21/2014, the Manufacturer only 
need to notificate 60 days (calendar days) early related to the beginning of the study, and 
can start the clinical investigation even if INFARMED, I.P. doesn’t pronounced itself. This 
law foresseens that INFARMED, I.P. must pronounce in 30 working days after the request 
notice for clinical investigation. However it also state that when any information request 
arise from INFARMED, I.P. the clock counting stops.  
(33)
 
1.2.1.3 Conformity Assessment 
In order to place on the market any MD the manufacturer should assess the conformity of 
the device, for that he needs to elaborate and collect all the necessary information which 
will constitute the Technical file. There isn’t a standard guidance for which documents or 
the precise information that must be present on the Technical file. However each of the 
Directives, applicable to MD, state what are the essential requirements that the 
manufacturer should fulfil. 
(2, 15, 16, 20)
 
Essential requirements are mandatory and seen as a necessary element for protecting the 
user’s interests. They are divided in general requirements of safety and performance issues, 
and specific requirements, which may apply or not to the particular MD. It will be up to the 
manufacturer to decide and justify the non-application of any essential requirements. In 
order to help the manufacturer to accomplish the conformity with the essential 
requirements, there is a set of harmonised standards. These are only technical 
specifications that the manufacturer should decide to follow or not. 
(2, 15, 16, 20)
 
When technical documentation is elaborated and the conformity was evaluated, then 
manufacturer may affix CE mark. Depending on the MD class, the conformity assessment 
may require an external evaluation (MD of medium to high risk). In those cases the 
manufacturer should submit an application to a NB, who, if the product is in conformity, 
will issue an EC Certificate, which allows the manufacturer to affix the CE mark. 
(2, 16, 18-20)
 
According to the MD class there is a set of conformity assessment procedures for obtaining 
the CE mark, Table 3 and Table 4 reflects the corresponding procedure to the MD 
classification. 
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Table 3 – Procedures for Conformity assessment of MD and AIMD (2, 16) 
Table 4 – Procedures for Conformity assessment of IVD (20) 
From the conformity assessment may result two kinds of documents which proves that the 
assessment was carried out and the product is in conformity, the EC Certificate and the 
Declaration of Conformity. Although the meaning it’s similar, there is a main difference 
between the two document. The EC Certificate it’s issued by the NB and is not applicable 
to all MD, and the Declaration of Conformity (See Annex B for minimum information), 
which is issued by the manufacturer and applicable to all the devices. 
(2, 16, 20)
 
Once the conformity assessment process is fully complete and the CE mark affixed, then 
the MD could be placed on the market. Additionally all the manufactures of class I device, 
should register theirs devices (class I) at the CA of the member state they are based in. For 
the remaining classes the manufacturer should have attention to the particularities of each 
country which may request, or not, the registration of the MD in the CA. Portugal requires 
Classes Procedures for Conformity assessment NB’s evaluation 
MD annex of Directive 93/42/EEC  
I VII No 
I sterile VII+ (II (without point 4); IV; V; VI) Yes 
I measure function VII + (II (without point 4); IV; V;VI) Yes 
IIa II (without point 4); VII +(IV; V; VI) Yes 
IIb II (without point 4); III + (IV; V; VI) Yes 
III II; III + (IV; V) Yes 
AIMD annex of Directive 90/385/EEC  
Active Implantable II; III + (IV; V) Yes 
Classes Procedures for Conformity assessment NB’s evaluation 
IVD annex of Directive 98/79/EC  
Others IVD III No 
Self-testing IVD III, point 6; IV; V + VII Yes 
List A IV; V + VII Yes 
List B IV; V + (VI;VII) Yes 
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the registration of all MD from class IIa to III which are placed in the national market as a 
foreseen duty of the manufactures. Although Directives only mention as mandatory the 
registration of some MD classification (or some information regarding IVD) to the national 
CA were the manufacturer is established. 
(2, 16, 18-20)
 
In order to all the process stated before may occur, it is necessary that the NB, to whom the 
manufacturer submits the application, is legally designated by one national competent 
authority for designation. 
(14)
 
The CAs can have as well an indirect role on the conformity assessment since they may 
participate on the designation of the NB. Any candidate to be a NB should apply for 
designation to the designating authority of the Member State where he is established. Since 
the introducing of the Regulation no 920/2013 that the evaluation of the candidate must be 
done by the national designating authority and two representatives of two others 
designating authorities from others Member States. As said the CAs may participate on this 
process since they may act as well as designating authorities, for example in Portugal the 
designating authority is INFARMED, I.P.
(34)
 
1.2.1.4 Market surveillance and vigilance 
1.2.1.4.1 National Competent Authority 
When talking about market surveillance of any medical device, the CA is responsible for 
monitoring the conformity of the products available in their market and of the 
manufacturer, and other players, located in their state. 
(18)
  
Regarding the market surveillance activities, according to the MD Directives, the member 
state is responsible for settle all the measures to ensure that the MD placed on the market 
are in accordance with the applicable legislation. In a general way this includes desk 
review, vigilance, inspection and laboratory control. 
(2, 35)
  
In Portugal these activities are carried by different units of INFARMED, I.P, desk review 
and vigilance are carried in DPS. However the remaining activities, inspection and 
laboratory control, are carried in other units. Due to different human qualification on the 
different units on INFARMED, I.P., laboratory control is done by the Control Laboratory 
unit, and the inspection are made by the resources of the Inspection and Licensing unit. By 
  
21 
one side laboratorial control its made to a product, and on the other side the inspecting 
acting is as well performed to the entities of the market and not only to the product. 
(35)
 
From the above stated activities for market surveillance, the only that will be focus here are 
desk review and vigilance. Those represents the activities carried out by DPS, the unit were 
the internship occurred. Despite that inspection and laboratory control may as well been 
carried in collaboration by the different units. 
Desk review may comprise activities like: 
(35-37)
 
 Evaluation of registries/notifications made by manufacturers and distributors; 
o Issuing of Registry Declarations; 
o Declaration for exportation purposes; 
o Codification project; 
o Elaboration and publication of MD’s list. 
 Campaigns for specific groups of medical device; 
 Documental review due to financial protocols with the Health Department; 
 Technical opinions for importation issues. 
 Cooperation with other national entities and European authorities.  
Regarding the vigilance activities, Portugal created the national system of MD’s vigilance 
in 2004, which is based on the Meddev regarding MD vigilance system and also on the 
pharmacovigilance system. The vigilance system is intended to: 
(38, 39)
 
 minimize the risks of MD use, by identify them on the real word; 
 encourage the notification of any incident, by any player of the lifecycle; 
 ensure the implementation of the corrective and preventive action taken by 
manufacturer; 
 and reunite, analyse and share the information with other CA and the EC.   
In the Vigilance system the CA should first of all encourage the notification of any 
incident by any individual involved in the life cycle of medical device. Because for the 
Vigilance system works efficiently it is necessary to report incidents, in order to have 
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feedback from the use of MD. This can be achieved by reinforce these issues to the health 
professional and users given them training or the necessary information. 
(40)
  
According to the Directive 93/42/EEC, all the national authorities should define and 
increment the routes in order to obtain the necessary information, and to disseminate it. 
Receiving the information is important, but transmitting it to the relevant stakeholder is 
also as important, and making that information reaches its destination can be harder than 
receiving it. 
(40)
 
When the CA receives notifications from the health professionals and/or users it should try 
to collect the maximum information possible and analyse it. When the notification fulfils 
the incident criteria (see Table 5) then the CA should inform the manufacturer about the 
incidents, without compromising the confidentiality of who notified. This is another way of 
ensuring that the events are being evaluated by the manufacturer. 
(40, 41)
   
Table 5 – Incident criteria to be met in order to notify the CA (39, 40) 
Incident criteria for notification* 
 An event occurred; 
 The incident may be related to the MD; 
 The event led, or might have led to one of the following 
outcomes: 
 Death; or 
 Serious deterioration in state of health: 
o Permanent incapacity or a threats to life; 
o Hospitalization, or increased time of hospitalisation, or medical 
or surgical intervention for prevent the damaged caused; 
o Foetal distress or death, congenital abnormally or malformation 
at birth; 
o Indirect harm, after an incorrect diagnose related to a MD. 
*must full the 3 criteria 
In general the investigation of the incident is carried out by the manufacturer, but the CA 
monitors this evaluation and also verifies if it’s needed to implement immediate corrective 
actions before the conclusion of the investigation. Besides to monitor, the CA can was well 
act on the action taken, by changing the direction of the investigation, verifying if the 
obtained results are enough or by recommend the alteration of safety information contained 
on the MD literature distributed to the public. Additionally, the CA can also perform their 
assessment of safety and performance of the medical devices, taking in account the tight 
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risk-benefit balance, for that they can rely on the reports of clinical investigations, and 
other information regarding the design and manufacture of the MD provided by the 
manufacturer.  
When the incident investigation is finished and the manufacturer propose a Field Safety 
Corrective Action (FSCA), the CA also evaluates if the action taken is enough. Once the 
manufacturer communicates a FSCA, the CA where the manufacturer is placed should 
inform the Commission and the others member states through NCAR (National Competent 
Authority Report) on EUDAMED (European Database on Medical Devices). 
(17, 40, 41)
 
1.2.1.4.2 Manufacturer’s Post market surveillance Plan and Vigilance duties 
When marketing a device, the manufacturer should implement a market surveillance plan 
and a vigilance system, which is integrated at its QMS. These post-market activities are, in 
the majority of the cases, integrated on the quality system of the manufacturer. Both the 
quality management standards (ISO 9001 and ISO 13485) and the risk management 
standard (ISO 14971) require the manufacturer to conduct post-marketing activities. This 
can be divided in two kind of activities: 
(18, 42)
 
 Proactive: considered as the activities contemplated on the post market surveillance 
(PMS ) plan; 
 Reactive: the vigilance activities, which may or not including complaint handling. 
Regarding the proactive activities, which mean doing something before it happens, it’s not 
specifically indicated which one the manufacture must adopt. It is the manufacturer 
responsibility to ensure that he is collecting all the information regarding the use of the 
MD. This needs to cover the quality, safety and performance of the MD. As important as 
the collect the information, it is important to assure that all the involved parties are trained 
on how to collect and document the information. 
(42, 43)
 
Activities may include the analysis of market trends, literature review, client inquiries and 
post-market clinical follow-up. However they need to be planned, which needs to be 
translating on procedures, on how to do it. Some of these activities (according to the MD 
associated risk) should be planned before placing the MD on the market, since it would be 
this planning that will be evaluated by the NB. These include a pre-defined periodic 
revision, which should integrate the clinical evaluation and the risk management. 
(44, 45)
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Like in other pharmaceutical sectors, the information gathered on the pre-market phase is 
only a little bit of we can know. And what happen when placing a MD on the market may 
differ from what were foreseen. Even if it didn’t differ, there is the need of continuous 
evaluate the balance between risk and benefit. Check if new risks appear or even if the 
ones foreseen on the risk management analysis, made prior to marketing, needs to be 
adjusted to the reality. This is a continuous analysis of the system, which on a simple 
quality system can be called as continuous improvement, that it is no more than a tool as 
well to maintain the good functionality of the business. For this reason, the results from the 
PMS plan should interact with the risk management system of the manufacturer. 
(42, 44)
 
The PMS plan should be documented in the forms of procedures that will ensure the 
gathering of the information. This could be included on the quality system of the 
manufacturer or done and included as specific procedures for a MD. This difference and 
the need for specific procedures should be evaluated according to the MD associated risk. 
(44)
 
Contrary to the proactive activities that may result on the early detection of signals, which 
conduct to the reduction of the possible events, the reactive activities are taken only after 
the event occurred. This can be detected during the analysis of complaints, or as well 
during vigilance activities. 
(43, 45)
 
The vigilance activities occur when an event related to the MD had occurred. Which means 
the manufacturer will only act after something happens, that’s why vigilance activities are 
reactive activities. As the responsible for the product, the manufacturer needs to notify the 
incidents to all the relevant CAs (where the device is placed) and the FSCAs to the 
National CA of the member state where they had occurred and where the manufacturer is 
located. 
(18, 40)
  
When a manufacturer knows that an adverse event has occurred with their devices, it 
should evaluate the nature of the event and verify if it needs to be notified to the CA (see 
Table 5). The manufacturer is the responsible to assess the need of a corrective action, and 
to implement it. As the responsible for the main investigation of the occurred event, the 
manufacturer should deliver an incident report to the CA that includes the investigation 
and the corrective actions to be implemented in order to minimize the risk of the MD. (See 
Table 6 for information about Portuguese timelines concerning notification) 
(18, 43, 46)
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Table 6 - Timelines established on the Portuguese National Law for notification to 
Competent Authorities 
(18)
 
1.2.1.4.3 Notified Body 
The main activity of the NB on the MD’s lifecycle is on the pre-market phase. However 
even without a truly active role on the post-market, NB are the entities that ensure that the 
manufacturer foreseen all the activities needed for PMS and vigilance.  
NB function as a support entity to ensure the quality of the vigilance and PMS procedures 
established by the manufacturer before market placement. In the post-market situation the 
NB should evaluate if the results from the PMS and vigilance activities have an impact on 
the EC certification, which means that if any result could change the result of the 
conformity evaluation. 
(40)
  
1.2.1.4.4 Distributor 
Although in the actual European directive the distributor isn’t mentioned anywhere, the 
Portuguese’s law involved the distributor in the vigilance system as well on the market 
surveillance (some country may as well had apply their own national’s laws).  According 
to national law, distributor should notify all the information they have related to an 
occurred event on the Portuguese market. 
(14, 18, 19)
 
Regarding the market surveillance, they are supposed to participate directly and indirectly 
on the market surveillances activities. According to the national law they should ensure 
Type of notification Timelines  
Initial report  
Death or high risk for health 10 days 
Other cases 30 days 
Final report After investigation conclusion 
Death or high risk for health 10 days 
Other cases 30 days 
Safety corrective action  
Death or high risk for health As soon as possible, even after the action was taken 
Other cases 2 days before been applied 
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that only the MD, which conforms to the applicable legislation, are made available in the 
market by them. Which means that the distributor should possess enough knowledge and 
information regarding the MD they are trying to sell, that allows them to verify its 
conformity. This could be done by verifying the correct affix of the CE mark on the 
product and the verification of the conformity documents (EC Declaration of Conformity, 
and EC Certificate, when applicable). 
(14, 18, 19)
 
The other role of the distributors is to notify to the CA all MD they are made available on 
the Portuguese market, as well with other information regarding those devices. This 
obligation of the distributors foreseen on the national law, allows the INFARMED, I.P. to 
know the Portuguese’s market. This will constitute a source of information for the 
activities of desk review of the CA, but as well a possible database in cases related to 
vigilance. 
(14, 18, 19)
 
1.2.1.4.5 Health professional and Users 
The health professional represents the main source of information regarding events. Been 
the ones who use the devices in the real world, and thus they are the ones who see things 
happening. According to the Portuguese national law, they are involved in the notification 
of the events to the CA, and if possible to the manufacturer and distributors. 
(17)
 
The role of the Health professional on the vigilance system is vital; however no legal 
requirement states that they must participate on the Vigilance system. Therefore, it is 
necessary to encourage them to actively notify the suspect events which they know about. 
(40)
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2 On-Job Training 
2.1 Market Surveillance 
As stated before, in the MD context the activities of a CA is mainly in the post-market 
phase of the MD life-cycle, both in market surveillance and vigilance of MD. Although 
vigilance may be considered a part of the market surveillance and since my internship was 
not related with vigilance activities, these activities taken by INFARMED, I.P. will not be 
issued here.  
Additionally to market surveillance or what can be considered as a complementary activity 
to market surveillance, INFARMED, I.P. also provide scientific and regulatory support, as 
far as its possible. During my internship I was asked to answer six information requests, 
one of which was not concluded until the end of the internship. These may come from 
different sources, from distributors, manufacturers, patients or other partners or economic 
agents. According to the source the type of information may also change, it can relate to 
the legal qualification of the products to simple doubts in one of the platform formats or 
legally binding. This had allow a different approach, than the usually related to the 
distributors’ registries, as I consolidate my knowledge and go even deeper on the 
regulatory affairs in the MD world. 
As for class III, IVD’s and AIMD that already have a public list of the distributors’ MD 
registered in the INFARMED, I.P.’s  site (47), the goal is to achieve the same for class IIb 
MD. However, in order to make publically available a MD listing is necessary to validate 
all the information given on the registries made until the moment, and keep updating the 
listing monthly. When I arrive at DPS, this work had already started, but however it was 
paused due to the lack of human resources. I also contribute to this validation, which had 
shown me different devices although from the same class, but a wide variety of devices, 
from anticoagulant sprays to condoms. 
Figure 8 represent my contribution to the class IIb’s list. Although it stills a long way to the 
release of the list, it represented a huge opportunity to explore the huge variety of devices 
that exists on the Portuguese’s market.  Although I had the chance to evaluate a huge 
number of registries, the reality is that my work as dependent of the collaboration of the 
distributors. By this way 394 registries stayed under evaluation, even after the duration of 
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my internship, for these registries an information request was made, however it was not 
possible to answer to the doubts (qualification, classification …), which could had been 
due to lack of response of the distributors, insufficient response, and/or proceeding to a 
COEN. 
Figure 8 – Class IIb registries analysed during 2014 (January-July) 
2.1.1 Codification project 
My main task during the internship was to provide backup to this big project that is 
occurring. This project was officially created on 2012, due to economic restriction present 
on the memorandum of understanding between Portugal, the European Commission, the 
European Central Bank and the International Monetary Fund. The codification project 
started by INFARMED, I.P in order to provide an in deep knowledge of the available 
information on the national database, when at the same time provides to the health 
professional more information related to the health technologies. Secondary it is foreseen 
that this project may as well increase the efficiency and the ability to negotiate the 
acquisition of the health technology. Besides the above mentioned purposes, stated on the 
Order no 15371/2012, the codification project purpose is also to allow the different players 
to communicate on the same language, avoiding confusion and disseminating product 
traceability. 
(48, 49)
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By the application of the Order no 15371/2012, services and entities belonging to the SNS 
can only acquire MD whose group was already been codified, which mean that it has a 
code attributed by INFARMED, I.P. . The codification process is made on phases, being 
the group (NPDM groups) order to be codified selected according the associated risk and 
the associated cost, both per unity and due to a broad utilization of that kind of device. 
(48, 
50)
 
The NPDM group is a Portuguese’s specific nomenclature for groups of MD, although it is 
based on other European nomenclature systems. These different groups allow to aggregate 
MD according to their intended use, the application site and their technological 
characteristics. 
(49)
 
In order to proceed with the codification of a new group of MD, a search is made on the 
available database (mainly on Distributor registries) for the detection of potential MD to be 
included on the new group. Internally the search’s results are evaluated, and another team 
contact the owner of the registries to notify them about the new group. In that stage, I was 
able to evaluate the results for the Ostheosynthesis and tendo-ligament synthesis devices 
group and the ligaments prosthesis. However only the ostheosynthesis group was release 
for public until the end of my internship. 
After this initial work of device selection, is necessary to validate the registry information. 
Since the code will only be given to the MD after the regulatory approval of the registry, 
and the validation by the codification team. Due to the obligation of obtain a code to the 
distributer, and in order to make it available for consultation by the SNS entities, the 
registries needed to be evaluated in a daily base. This regulatory evaluation is made 
similarly to the one made to obtain the Registry Declaration. From the data available on the 
registries, and the submitted documentation, it is possible to evaluate the product 
qualification and classification, as also check some of the requirements for placing MD 
into the market. Basically the codification process is based at the same principles of market 
surveillance, the registration of the information to prior validation. 
As said above the registries were daily evaluated by the regulatory team, based on the 
already released groups, and secondly on the upcoming groups. Table 7 shows the groups 
of MD released until the end of the internship. 
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Table 7– Groups of MD with codification process completed (at the end of the 
internship) 
(50)
 
At the beginning of the internship the above groups were split according to at seems to be a 
logical and functional combination of groups (see Table 8). Some of them were combined 
into major groups, given the similarities of the groups. As the groups were divided, then I 
start to evaluate the registries associated to the codification process. 
 
Groups 
Available  
since 
Groups 
Available 
since 
AIMD of cardiac function  07.02.2013 Implantable pumps 02.09.2013 
Hip prosthesis 15.02.2013 Neurostimulators 08.10.2013 
Knee prosthesis  15.02.2013 Hearing AIMD 08.10.2013 
Intraocular lens 28.02.2013 AIMD - Other 08.10.2013 
Heart Valves 31.03.2013 Peripheral vascular stent 20.10.2013 
Coronary Stents 31.03.2013 Foot prosthesis 20.10.2013 
Vascular endoprosthesis 30.04.2013 Ankle prosthesis 20.10.2013 
Prosthesis for coronary and 
heart defects 
30.04.2013 Hand prosthesis 20.10.2013 
Cochlear implants 30.04.2013 Wrist prosthesis 20.10.2013 
Shoulder implants 30.04.2013 Elbow prosthesis 20.10.2013 
Breast implants 01.07.2013 Ear prosthesis 20.10.2013 
Surgical meshes 01.07.2013 
Spinal stabilization system 
and prosthesis 
29.10.2013 
Vascular Patches  01.07.2013 Urogenital prosthesis 02.12.2013 
Cardiac and Vascular 
prosthesis - accessory 
01.07.2013 Tissue extenders 02.12.2013 
Surgical sutures 02.09.2013 Tissues Patches 02.12.2013 
Vascular prosthesis 02.09.2013 
Ostheosynthesis and tendo-
ligament synthesis devices 
03.02.2014 
Adapted from the codification site 
(50)
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Table 8 – Group distribution for regulatory review 
My groups My colleague groups 
Code Group Code Group 
P0901 Shoulder implants J01 AIMD of cardiac function 
P0902 Elbow prosthesis J02 Neurostimulators 
P0903 Wrist prosthesis J03 Hearing AIMD 
P0904 Hand prosthesis J04 Implantable pumps 
P0905 Ankle prosthesis J99 AIMD - Other 
P0906 Foot prosthesis P0301 Intraocular lens 
P0907 
Spinal stabilization system 
and prosthesis 
P06 Breast implants 
P0909 Knee prosthesis P07 Cardiac implants 
P0912 
Ostheosynthesis and tendo-
ligament synthesis devices 
P08 Urogenital prosthesis 
 
P9001 Tissue extenders 
P9002 Surgical meshes 
P9003 Vascular Patches 
P0201 Ear prosthesis 
C0104 Cardiovascular MD 
H01 Surgical sutures 
P0908 Hip prosthesis 
 
First it is necessary to obtain the registries that are associated to each of the groups. In 
order to have access to those registries, the groups’ code was searched in the backoffice 
(see Figure 9). The results were then displayed by references, however in the original 
database we aren’t able to search for reference.  
Associated to the reference is an ID number, this is the registry identification. Each ID may 
contain multiple references, if they represent the same MD. So what we will obtain is an 
extensive listing of references, where the interest is on the ID. Each ID is then searched at 
SDIV (see Figure 10 and Figure 11) 
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Figure 9 – Backoffice of Distributor’s database for the codification process. 
 
Figure 10 – SDIV layout 
There, and in accordance to the Manual for On-line Registration 
(51)
, should be available 
the information regarding Designation, Classification, NB code, trademark and model, and 
GMDN code or Brief Description. 
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Figure 11 – Information obtained from SDIV, specific for each device 
 Designation (“Designação”) – correspond to the common name given to the MD; 
 Classification (“Classificação”) – defined by the MD’s  manufacturer, according to 
the applicable Directive; 
 NB code (“Código Organismo Notificado”) – NB responsible for the conformity 
assessment of the MD, if applicable; 
 Trademark/Model (“Marca/Modelo”) – commercial name/identification; 
 GMDN code (52)– it’s a Global Medical Device Nomenclature (GMDN), which aim 
to provide a single naming system (generic) for help in support patient safety (by 
providing harmonized terms); 
 Brief Description (“Breve Descrição”) – any MD feature which distinguishes it 
from the others. 
After evaluate the above information, and to assess if everything is alright (for example 
intended use against classification, which also influence the presence or not of a NB code), 
then the codification team may also perform their corresponding validation. Codification 
team will be responsible for assess some of the information in the labels and Instructions 
for Use, such as reference and manufacturer. After the evaluation a unique code (CDM) for 
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the pair manufacturer/reference will be attributed, and so the MD and that specific 
reference may be acquired by the hospital or other SNS entity. 
The following Figures and Tables show the number of analysed registries during the entire 
internship. 
Table 9 – Registries analysed during 2013 (November-December) 
Group Validated
a
 Evaluated
b
 Information request Concluded in 2014 
P0901 3 0 0 0 
P07 3 0 1 0 
P0904 1 0 0 0 
P0908 3 0 0 0 
P0903 1 1 1 1 
P0909 58 5 12 2 
C0104 16 5 7 5 
P0902 1 11 11 11 
P0912 141 73 40 38 
P0907 723 43 87 43 
a registries validated (may include registries for which were necessary to require information);  
b include eliminated or discontinued registries and registries which weren’t validated (lack of response, 
errors in registries, …) 
Table 10 - Registries reviewed during 2014 (January-July) 
Groups Validated
a
 Evaluated
b
 Information request Under Evaluation 
H01 3 0 0 0 
J01 11 0 2 0 
P0301 6 0 0 0 
P07 3 0 0 0 
P08 1 0 0 0 
P0901 36 10 23 10 
P0902 6 4 7 4 
P0903 1 0 0 0 
P0904 6 1 1 1 
P0905 3 0 0 0 
P0906 7 0 3 0 
P0907 532 23 144 23 
P0908 8 1 2 1 
P0909 61 6 11 6 
P0910 2 0 0 0 
P0912 1218 64 146 59 
a registries validated (may include registries for which were necessary to require information);  
b include eliminated or discontinued registries and registries which weren’t validated (lack of response, 
errors in registries, …) 
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Figure 12 - Registries analysed during 2013 (see Table 9) 
These numbers represent the analysed registries during the internship at INFARMED, I.P., 
however this does not represent the entire work made under the codification project. First 
they are only related to the groups I was responsible for, and even if on some groups there 
is a considerable amount of validated registries, the reality it there is lot of work behind 
these numbers. 
From the first analyse of the registered information until the validation of the registry, 
there are exchange of information between the authority and the distributors, in the cases 
where there are any doubts of its conformity. This results on many registries staying on the 
classification of evaluated, which means the doubts where not solved but it’s still working 
on solving them (under evaluation), or in the other hand the doubts were solved, so they 
were non-conforms (eliminated) or they aren’t distributed anymore (discontinued). 
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Figure 13 - Registries reviewed during 2014 (see Table 10) 
The groups with the highest evaluated registries were without doubt the ones related to 
ostheosynthesis (P0912) and to spinal prosthesis (P0907) (see Figure 14). Both are mainly 
class IIb device, since they are implanted device intended to stay more than 30 days in the 
body, which require a mandatory NB assessment. However other class may apply, from a 
class I to III, depending if there is a reusable instrument (class I), or if any part is supposed 
to be absorbed by the human body (class III). 
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Figure 14 - Comparative representation of most evaluated groups (during all 
internship), see Table 8 for code group 
Additionally to the validation and evaluation of registries made by distributors under the 
codification project, and due to the huge amount of registries there were the need for 
issuing Registry Declarations, as foreseen in the Order no 15371/2012 
(48, 50)
. These 
declarations are issued for a specific public tender, when the registries are already 
validated (regulatory validation), however it’s not possible for the codification team codify 
the desired references in a timely way. 
I had received a total of seven requests for Registry Declarations according to the Order no 
15371/2012, however only two were issued. This huge difference happens due to the 
applicable rules, and also of the collaboration between the working teams. The first thing 
to do when we receive a request is to verify if the identified group of device are already 
under the codification project and if the group is released, if one of the principles fail, then 
the declaration will be not issued since it is not applicable. After this verification we check 
the status of the registry. Then the codification team is asked to codify the registries in a 
timely way. If the codification team can’t codify the registries, then the declaration will be 
issued. In the other hand if the codification is possible then the codes will be made 
available for the distributor. 
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From the seven requests above mentioned three were related to MD which group wasn’t 
been released until the date of internship’s end, as so the Registry Declaration, according to 
Order no 15371/2012, does not apply. 
 
As said this project had constitute the major part of my internship, it allowed me a full 
understand of the duties of the national distributors. As also providing a deep knowledge of 
how the platform works, regarding the notification process, and how the registries will be 
evaluated.  
But even more important, was the understanding of the necessity of knowing the deep 
market that is the medical device, especially the ones operating on our national market. 
This knowledge and the tools that the national CA have in a distributor level, revealed a 
strong potential, and a useful tool for market surveillance. As well for the vigilance system, 
since it allow some traceability in the national cases but also the ones that came from the 
other European’s CA.  
First the obligation of the distributor to registry the device they sell, already provided some 
of the knowledge of which are the MDs operating in our national market, allowing a fast 
and efficient way for public health protection. And I’m not talking only about cases were 
the MD was found to be prejudicial, or the risk/benefit analysis turned negative. Since the 
validation of the registries is made, it’s also possible the detection of nonconformity of 
products on the market, by safety issues, or even only by a wrong qualification. 
Now with the codification project the registries are validated daily, which mean for the 
codified groups the registries are always up-to-date. The desk review is made daily 
allowing the CA to know the recent MD placed on our market. With the codification 
project the traceability of the MD goes even further, as it allows an easier way to know all 
the entities involved on the distribution of a certain MD. But since the SNS entities can 
only buy MD with a CDM code (when applicable), and are supposed to use this code as an 
internal reference, the application of the codification project will provide the traceability 
including on the hospital level. As said this is of great importance in cases were the Public 
Health, or even individual health may be compromised. Since it allows the traceability of 
the devices, from the health entity which used it, until the manufacturer and all the entities 
that are on between. 
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2.1.2 Registry Declaration 
As foreseen in the Decree-Law no 145/2009, it’s a distributor obligation to notify 
INFARMED, I.P. all MD that he made available in the market.
(18)
 The way distributors 
have to prove they accomplish this obligation, it’s by way of a Registry Declaration issued 
by INFARMED, I.P. (for those MD not belonging to class III, AIMD or IVD, and not yet 
under the codification project). Having this certificate means that their device, whose are 
mentioned in it, are registered and their information is valid. 
(46)
 
In order to obtain this certificate the distributor needs to request it to daps@infarmed.pt, 
and then it will be attributed to one of the DPS’ collaborators. Due to an overwork season, 
it was asked to help the colleagues responsible for issuing the Registry Declarations. I end 
up issuing one Registry Declaration. 
The issued certificate was related to 34 registries from one distributor. From that 30 
registries were needed to be modified. In order to correct the registries it was needed to 
request information to the distributor, the first request were made in December of 2013, 
and the certificate were issued in February of 2014. Between the two dates, a lot of emails 
were exchanged and a lot of explanations were done, regarding both the registration system 
itself, but also the regulatory qualification and classification of the MD. This had 
represented my first Registry Declaration, which timelines were unusually, due the 
numerous stops on the clock for information requests.  
The normal timelines for the issuing of the declaration is 10 working days. However the 
counting stops every time an information request is made in order to validate the registry 
or if the given information is not according to the applicable legislation. 
(46)
  
The Registry Declaration is the original way of validating the registries, as well of the SNS 
entities ensure that the MD are according to the law. It is supposed that this kind of 
declaration will ended, since the main purpose is to be able to attribute a CDM code to all 
MD.  
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2.2 Interaction between competent authorities 
2.2.1 Inquiries and COEN’s 
Due to the free movement of goods on the European market, which MD benefits from, it’s 
difficult to know exactly everything that is circulating on that market. Even a MD that is 
not usually encounter on a national level may enter the national market. In order to this 
free movement of goods may occur and at the same time protect the public health it’s 
crucial that all the European’s CA cooperate between them. The cooperation and the 
dialogue between the involved parties make possible the accurate exchange of information. 
Not only related to which kind of devices are on the market, but as well related to new 
information regarding the MD’s risk. 
There is two official ways of exchange information between authorities. And although I 
hadn’t answer or elaborate any inquiry, I had the opportunity to look some, in a try to get 
more specific information, as also different perspectives, related to the product I was 
analysing at the moment. They are elaborated in cases where there are doubts on the legal 
qualification and/or on the risk classification of the device. The inquiries are spread 
between all the member states to obtain the desired information/opinion on a group of MD. 
In the other hand COEN is a more specific way to exchange information between CAs. It’s 
related to a MD or groups of devices for questions related to its conformity. I had filled out 
two COEN2 forms for which I did not receive the answer during my internship. One were 
related to claims made at the labelling and packaging of a MD which may induce in a 
pharmacological action, and thus the product will not been a MD. Since the manufacturer 
is located in another European country, INFARMED, I.P. couldn’t act directly, so the 
solution was to communicate with the CA of that country. That situation clearly refers to 
the elaboration of a COEN since its specific for one product and directed to one CA for a 
specific issue of MD conformity. 
The other COEN2 is related to shoulder resurfacing prosthesis that were classified by the 
manufacturer as a class IIb. However in our understanding they should belong to class III 
MD according to the Directive 2005/50/EC, which reclassify the shoulder joint 
replacements as a class III MD. After verify the documentation and the argument of the 
manufacturer for the attributed classification, we had decide to ask the opinion of the 
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national CA from which the manufacturer it’s based. In this case it’s not so clearly why a 
COEN was choose instead of an inquiry, since the inquiries are the ones used in 
classification issues. This is actually a controversial issue since the directive state that total 
joint replacement of the hip, knee and shoulder must be classified as class III. However it’s 
still accepted some prosthesis as IIb, when manufacturer argues that they are not a total 
joint replacement only part of the joint, and their intended use it’s only for parts of the 
joint. That was the main reason to use a COEN instead of an inquiry. Try to collect the 
opinion of the CA where the manufacturer were located, about that specific product, and 
not all the resurfacing prosthesis. However until the end of my internship, I didn’t obtain 
an answer to the last COEN2 form that was sent. 
(53, 54)
 
Although the importance of the collaboration between entities represents a keypoint to the 
harmonisation of the market, I was unable to obtain an answer. This was one of the 
struggles pointed and also felted. Although the mechanisms for CA interaction exist the 
reality is that it takes times to obtain an answer. Additionally on the previous interactions 
some of the obtained answers were too evasive and not really justified. Although this 
represents useful tools, they aren’t the more efficient ones. They limit the CA ability to 
respond or to obtain an answer in a reasonable time, which keeps some process to proceed 
further. 
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3  Discussion and Conclusion  
During my internship a high positive interaction was present in a daily basis. I had the  
possibility of discuss any subject with working colleagues, this surprisingly increased the 
knowledge obtained in the internship, but also had allow a further understanding regarding 
the way of thinking in MD. Additionally the multidisciplinary team present at DPS is a 
plus on the MD field, since it conducts to a better discussion with different levels of 
knowledge and views allowing a more in deep understanding of the subject and the device. 
This way of working is very effective since it spread the knowledge, but also represents an 
extra motivation, since it allows a constant challenging of the collaborators. 
Although this entire work environment that allows the easily exchange of information, the 
reality is that my internship was more focused on the validation of the distributor’s 
registries. It was not possible to had work experience on the other MD’s duties of DPS. I 
consider this as a weakness of the internship, since it didn’t allow a more broad approach. 
Nevertheless the goals of the internship that were present at the beginning were fulfil. And 
even if they were not contemplating as practical issues, in the end I was still able to retain 
some of that information. This was provided both at the initial theorical training and as 
well on the thematic mornings where all the members of the team could exchange practical 
information, and even discuss it, with each other. These thematic mornings were done on a 
weekly basis, and were crucial to maintain all team members update, including on new 
regulatory feedback. As said I felt  like been only focuses on the validation of the registries 
has a little limited to all we can learn related to MD, however these thematic mornings had 
exceed some of that limitation. 
Nevertheless I recognize that on a country made mainly of distributors, the national 
database is of great value. It allows the knowledge of the market that can be very difficult 
to have, due to all the variety of the products. And this knowledge is of great importance 
for the protection of the public health. By knowing what is circulating on the market, 
INFARMED, I.P. can act much faster in cases of incidents reported outside the country or 
even on the ones reported here.  It allows as well verifying if the product that are available 
to the public are in conformity, acting as a proactive measure to ensure the public health. 
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This was with the initial database, now with the codification project the traceability of the 
device and the market knowledge goes even further. First the devices belonging to a 
codified group are evaluated on a daily basis, which mean the conformity (desk review 
based on the literature provided) is checked daily. Additionally the traceability can go until 
the hospital level, meaning a better control in cases where it’s needed. With the 
codification project the traceability allows an even faster action in situation where the 
public health is compromised, and can go as well to the level of the individual health, 
according to the quality of the hospital’s registries. 
In order to the codification project continues improving, it’s very important the interaction 
between the two teams, codification and the regulatory team. More only than a merely 
interaction, it’s important that the two teams are able to work together. Creating the same 
criteria to apply to all cases, even on the cases where a Registry Declaration is needed. 
During my internship the interaction between the teams were done by phone, and only for 
solving particular issues. For teamwork is important to increment positives interactions 
between the parties, ensuring that all the members are there for the same reason and that all 
understand the goal as only one, not like the individual perspectives of each one, even if on  
the practice they are doing different things. And although the two teams were working for 
the same final goal, there were different perspectives of what were important, and the 
desired outcomes, to the different team.  
When I started the internship my knowledge related to MD was very limited, however as 
soon as I start to explore this new regulatory world, I kind of fall in love with it. I was 
presented with a huge variety of products and different application, which can vary 
between simple technologies to complex ones. Besides this huge variety, it had also 
allowed to understand how spread medical devices are in our daily life. MD represents a 
surprising amount of health solutions and we even don’t totally understand the additional 
value of MD for public health. As said by MedTech “Medical Technologies is there 
throughout your life, from before you are born until the end of your life”. And the reality is 
that even if you don’t know we always use or will use a MD or even more than one. (55) 
MDs are constantly evolving, changing, and challenge itself. It kind of comprises a cycle 
of continuous improvement, both due to technological advances and also deeper 
  
45 
knowledge related to Health Sciences. There are even more different types of technologies, 
things that in the past we didn’t dream of or think they were actually a MD.  
This constant evolution of the sector also brings some of the fragilities of the system to the 
surface. This happens mainly because what is laid down in the legislations is actually 
corresponding to the past knowledge and applied to a huge variety of products. Leading to 
a constant revision of the applied standards, which are better obtained with discussion 
between the different parties, the regulatory bodies and also by the manufacturers, who 
actually have the knowledge of the technology. However this discussion it’s only possible 
to be done in relation to the products we already know, that are already in the market, even 
if before they weren’t considered as MD. Additionally if we add the bureaucratic process 
to approve any kind of legislation to the MD market, what will happen is that what is been 
regulated is actually the knowledge associated to the products when the discussion started 
and not the ones corresponding to the newer technologies. This leads to legislations that 
only regulate the previous products/knowledge, the ones at the beginning of the discussion. 
Although what mention above is a fragility, it also represent one big opportunity. This lack 
of ability to predict the products that will appear on the market, associated to the higher 
speed of new health technologies, only allows the discussion groups to harmonise what is 
already on the market. Creating a grey area where it is not possible to restrict new products 
to reach the market, if they fulfil the MD definition, even without having any guidance or 
legislation for that product. That is exactly why this market is always growing, even with 
all the legal requirements, there is always a space for new things, new improvements and 
new inventions. 
In this field is extremely important, for the professional working in it, to always stay up-to-
date, which is a little difficult with all the changes occurring at the technological level, but 
as well as in the regulatory. From new kinds of devices to new requirements, like the ones 
comprised on the proposal regulation that is coming, from the Unique Device 
Identification to the products accepted under the MD regulation that do not present a 
medical intended. However difficult turns on the curiosity and the challenging factor in the 
human being. And was exactly what the internship had done with me. It had introduced me 
to this regulatory framework, had made me stay focus and enthusiastic about medical 
devices’ issues. 
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For all of this I can say that from my experience in the INFARMED, I.P., I brought a 
passion, a field in which I desire to work. As far as my knowledge allows me, MD field 
seems as a challenging world, which, if the professional know how to take profit from it, 
allows professional and personal growth. 
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